Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Relmada Therapeutics Q3 2026 Results: Net Loss of $13.9M, Loss Widens

Relmada Therapeutics reported a net loss of $45.8 million for the nine months ended September 30, 2026, compared to $37.5 million in the prior year, driven by increased research and development costs. The company significantly strengthened its balance sheet through common stock issuances, ending the period with $202.1 million in cash and short-term investments.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-13.9-10.1
EPS (diluted, $ a share)$-0.12$-0.30

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: RLMD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Relmada Therapeutics, Inc.: key numbers

Share price
$3.61Close, Nov 16
Market cap
$385M
Shares outstanding
106.69MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Relmada Therapeutics, Inc.

All →
8:01 AM ET 8-K
Leadership Change

Relmada Therapeutics Leadership Change

Relmada Therapeutics appointed Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer, Urology & Uro-Oncology. Dr. Jakobsen previously led the global clinical development of ADSTILADRIN at Ferring Pharmaceuticals and will now lead Relmada's planned Phase 3 SPECTRUM registrational program for NDV-01 in bladder cancer.

4:11 PM ET 8-K
Financial Results

Relmada Therapeutics Financial Results

Relmada Therapeutics reported third quarter 2026 financial results and provided a corporate update on its NDV-01 and sepranolone programs. The company ended the quarter with $202.1 million in cash, which is expected to fund operations through 2029, and remains on track to submit an IND for NDV-01 by year-end 2026.

“Relmada has made significant progress in advancing the NDV-01 CMC program and remains on track to submit the NDV-01 IND by year-end 2026. Furthermore, we have established a manufacturing plan to provide uninterrupted clinical supply through the completion of the Phase 3 SPECTRUM program.”

Sergio Traversa, Chief Executive Officer of Relmada Therapeutics

“Initial 18-month results from the ongoing NDV-01 Phase 2 study demonstrate extended durability of complete response and continued favorable tolerability. Our Phase 3 program remains unchanged, with two independent registrational pathways in NMIBC, and we have renamed it SPECTRUM to reflect the potential breadth of NDV-01 across the NMIBC disease spectrum. We expect to begin the SPECTRUM program upon IND clearance.”

Bipin Dalmia, Chief Business Officer of Relmada Therapeutics

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.